Sharma Pranav, Zargar-Shoshtari Kamran, Pow-Sang Julio M
Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Office 12538, Tampa, FL 33612, USA.
Future Sci OA. 2015 Dec 17;2(1):FSO72. doi: 10.4155/fso.15.72. eCollection 2016 Mar.
Prostate cancer (PCa) has variable biological potential with multiple treatment options. A more personalized approach, therefore, is needed to better define men at higher risk of developing PCa, discriminate indolent from aggressive disease and improve risk stratification after treatment by predicting the likelihood of progression. This may improve clinical decision-making regarding management, improve selection for active surveillance protocols and minimize morbidity from treatment. Discovery of new biomarkers associated with prostate carcinogenesis present an opportunity to provide patients with novel genetic signatures to better understand their risk of developing PCa and help forecast their clinical course. In this review, we examine the current literature evaluating biomarkers in PCa. We also address current limitations and present several ideas for future studies.
前列腺癌（PCa）具有多种生物学潜能，有多种治疗选择。因此，需要一种更个性化的方法，以更好地界定患PCa风险较高的男性，区分惰性疾病与侵袭性疾病，并通过预测进展可能性来改善治疗后的风险分层。这可能会改善有关管理的临床决策，改进主动监测方案的选择，并将治疗的发病率降至最低。发现与前列腺癌发生相关的新生物标志物，为向患者提供新的基因特征以更好地了解其患PCa的风险并帮助预测其临床病程提供了机会。在本综述中，我们研究了评估PCa生物标志物的当前文献。我们还讨论了当前的局限性，并提出了未来研究的几个思路。
